Novavax (NASDAQ: NVAX) reported Q1 EPS of ($0.29), $0.02 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $10.39 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.